Moreover, vascular normalization with VEGF/VEGFR inhibitors combined with PD-(L)1 blockade has demonstrated clinical efficacy across a variety of tumor types in phase III trials and is already FDA-approved in NSCLC, renal cell carcinoma (RCC), endometrial carcinoma, and hepatocellular carcinoma. Here, CD274 is linked to hereditary clear cell renal cell carcinoma.